NSE: AJANTPHARM | BSE: 532331

Mid-range Performer

Download real time

2424.70 -40.50 (-1.64%)

Near 52W Low of ₹2327.30

100.3K NSE+BSE Volume

NSE 29 Sep, 2025 3:31 PM (IST)

30,287.4

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Ajanta Pharma Ltd.

03 Nov 2018

2424.70

-1.64%

Ajanta Pharma Ltd Q2FY19 results Comment

Results Update: Ajanta Pharma Ltd.

HDFC Securities

Ajanta Pharma Ltd Q2FY19 results Comment Revenue increased by 6.48% to Rs. 544.11 Cr in Q2FY19 when compared to the previous quarter. Also, it rose by 0.69% when compared with Q2FY18

Ajanta Pharma Ltd. has lost -27.25% in the last 1 Year

Ajanta Pharma Ltd.

01 Nov 2018

2424.70

-1.64%

Ajanta Pharma-Result Update

Buy: Ajanta Pharma Ltd.

Reliance Securities

Ajanta Pharma (AJP) has delivered a better-than-expected performance on all operational metrics in 2QFY19 led by strong sales growth in Asia/US as well as lower-than-expected decline in Africa sales. Domestic business reported flat growth due to high YoY base led by channel re-filling post GST roll-out. Despite marginal sales growth, AJP's EBITDA de-grew by 9.5% YoY to Rs1.7bn on account of higher staff and other operating expenditure, owing to which EBITDA margin contracted by 345bps YoY to 30.5%. However, AJP's gross margin expanded by 255bps YoY to 82.4% due to better product-mix. Led by higher taxes, PAT de-grew by 4.9% YoY to Rs1.3bn. The Company is expected to file 10-12 ANDAs with the USFDA in FY19E. LPC maintained...

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

01 Nov 2018

2424.70

-1.64%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Recommendation Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Ajanta Pharma's Q2FY19 results were above I-direct estimates on all fronts mainly on account of a beat in export sales and higher other income. Revenues grew 0.7% YoY to | 544.1 crore. Muted growth was mainly due to the high base of restocking in domestic market post GST implementation and shrinking in African tender business. Beat vis--vis I-direct estimates was due to strong US sales EBITDA margins contracted 345 bps YoY to 30.5% (I-direct...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Aug 2018

2424.70

-1.64%

Ajanta Pharmaceuticals

Hold: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 8% YoY to | 511.0 crore (I-direct estimate: | 473.6 crore) mainly due to 24.5% YoY growth in domestic formulations to | 178.0 crore (I-direct estimate: | 175.0 crore) and 34.4% growth in Asia business to | 129 crore (I-direct estimate: | 134 crore) EBITDA margins improved 320 bps YoY to 30.8% (I-direct estimate: 25.8%) mainly due to strong gross margins and lower other expenditure. EBITDA grew 20.5% YoY to | 157.5 crore...

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

01 Aug 2018

2424.70

-1.64%

Ajanta Pharma - 1QFY19 Result Update

Buy: Ajanta Pharma Ltd.

Target

Reliance Securities

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

16 May 2018

2424.70

-1.64%

Ajanta Pharma Ltd Q4FY18 Results Comment

Results Update: Ajanta Pharma Ltd.

HDFC Securities

Revenue fell by 9.67% to Rs. 530.31 Cr in Q4FY18 when compared to the previous quarter. Ajanta Pharma Ltd Q4FY18 Results Comment

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Ajanta Pharma Ltd.

04 May 2018

2424.70

-1.64%

Ajanta Pharma - 4QFY18 Result Update

Buy: Ajanta Pharma Ltd.

Target

Reliance Securities

Despite lower-than-expected growth in domestic formulations business, Ajanta Pharma (AJP) has delivered a better-than-expected sales performance in 4QFY18 led by strong growth in African branded business. Gross margin improved by 167bps YoY due to better product mix. However, reported EBITDA margin was below our estimate (26.3% vs our estimates of 28.3%) due to higher than expected employee cost and other expenses related to newly commissioned facilities (Guwahati and Dahej). EBITDA was down 13.6% YoY to Rs 1.4bn (in-line with our estimates) which drove PAT decline of 17.1% YoY to Rs 945mn (below our estimates of Rs 991mn). As per the Management, the Company would file 10-12 ANDAs with the US FDA in FY19. Domestic business...

Number of FII/FPI investors decreased from 385 to 371 in Jun 2025 qtr

Ajanta Pharma Ltd.

10 Apr 2018

2424.70

-1.64%

(REVISED) AJANTA PHARMA LTD.

Buy: Ajanta Pharma Ltd.

Target

Choice India

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Ajanta Pharma Ltd.

06 Apr 2018

2424.70

-1.64%

AJANTA PHARMA LIMITED

Buy: Ajanta Pharma Ltd.

Target

Choice India

Valuation: At CMP of Rs. 1391.8mn, Ajanta Pharma Ltd. is trading at a P/E multiple of 25.2(x) compared to the industry peer of 27.6(x). The company has an upside potential of 25% to 30% in the next 12 to 18 months. We arrive at a target price in...

Prabhudas Lilladhar released a Buy report for Ajanta Pharma Ltd. with a price target of 3200.0 on 19 Sep, 2025.

Ajanta Pharma Ltd.

22 Feb 2018

2424.70

-1.64%

Ajanta Pharma: Growth ingredients in place; EM execution + US approvals hold key

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

We recently met Ajanta Pharma's (AJP) management to get updates on its business segments. Rejigged strategies by the company in a favorable business environment have started yielding results in Asia, while its enhanced focus on Anglo Africa is expected to support growth in Africa???s branded generics business. AJP has also re-strategized to improve growth in dermatology in the domestic formulations segment, and remains on track to outperform industry. We maintain our estimates and re-iterate our Buy rating, with a price target of INR1,840, driven by superior execution in branded generics and a robust product pipeline for the US market.

Promoters pledged 1.51% of shares in last quarter. Total pledge stands at 14.12% of promoter holdings

Is Ajanta Pharma Ltd. worth buying?

189 Votes:

Buy 77.25%

Sell 15.87%

Hold 6.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf